Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia (NF1TD)
This study is currently recruiting participants.
Verified by Shriners Hospitals for Children, May 2008
Sponsors and Collaborators: Shriners Hospitals for Children
University of Utah
Information provided by: Shriners Hospitals for Children
ClinicalTrials.gov Identifier: NCT00303368
  Purpose

The study is a multicenter four-year outcome study of the natural history of tibial dysplasia in patients with NF1 and selected patients without NF1. We will obtain information on the natural history, burden, functional and health status, health-related quality of life, and surgical interventions/outcomes of tibial dysplasia. The project will also establish a Core Facility (NOCF) for tissue samples for future studies.


Condition
Neurofibromatosis Type 1
Tibial Dysplasia

Genetics Home Reference related topics: familial encephalopathy with neuroserpin inclusion bodies neurofibromatosis type 1 neurofibromatosis type 2
MedlinePlus related topics: Neurofibromatosis
U.S. FDA Resources
Study Type: Observational
Official Title: Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients

Further study details as provided by Shriners Hospitals for Children:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

If the enrollee's private physician includes surgery in the management of his/her disorder, and if tissue is removed to be discarded, permission is obtained to store the specimen in a tissue repository for future research.


Estimated Enrollment: 420
Study Start Date: March 2004
Estimated Study Completion Date: December 2008
Detailed Description:

The three specific aims of this study are:

  • Specific Aim 1 - To assess health status and health - related quality of life (HRQL) in 50 children and adolescents with NF1 and tibial dysplasia and in NF1 controls. We hypothesize that children and adolescents with NF1 and tibial dysplasia will experience an additional burden of morbidity due to tibial dysplasia and a downward trajectory of health status and HRQL over time.
  • Specific Aim 2 - To assess the long term outcome of current treatment in 100 adult patients diagnosed with NF1 and tibial dysplasia in childhood. We hypothesize that better quality of life and function, in adults with NF1 and tibial dysplasia, are associated with amputation in childhood compared to multiple surgical procedures, the lack of fibular involvement, and fracture later in childhood. We also hypothesize that individuals with NF1 and tibial dysplasia have a higher risk of other bony dysplasias but are at no higher risk of fracture in other bones.
  • Specific Aim 3 - To assess the natural history and short-term response to therapy in a cohort of at least 60 children with NF1 and tibial dysplasia and at least 60 children with tibial dysplasia presumably without NF1 prospectively diagnosed during the course of the four-year study period. We hypothesize that NF1 patients with earlier presentation, Crawford Class II A-C, male gender, and the lack of bracing prior to age two are more likely to fracture. We also postulate that individuals with and without NF1 have a similar outcome and response to treatment.

The results of this project will provide a rational basis for future clinical and therapeutic trials.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults and children with NF1, with or without Tibial Dysplasia, ages 3+ and individuals ages birth through 18 with Tibial Dysplasia, with or without NF1.

Criteria

Inclusion Criteria:

  • Aim 1:

    • Group 1, NF1 with Tibial Dysplasia, Ages: 3-18
    • Group 2 (control), NF1 without Tibial Dysplasia, Ages 3-18
  • Aim 2: NF1 with Tibial Dysplasia, 19+
  • Aim 3: Tibial Dysplasia with or without NF1, Ages: birth to 18
  • Tissue procurement, any participant undergoing surgery at the tibial site for routine standard of care

Exclusion Criteria:

  • Patients without a diagnosis of NF1 or Tibial Dysplasia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00303368

Contacts
Contact: Jeanne A Siebert, MBA 801-536-3601 jsiebert@shrinenet.org
Contact: Susan J Geyer, BA 801-536-3561 sgeyer@shrinenet.org

Locations
United States, Utah
Shriners Hospitals for Children, Intermountain Hospital Recruiting
Salt Lake City, Utah, United States, 84103
Contact: Jeanne A Siebert, MBA     801-536-3601     jsiebert@shrinenet.org    
Contact: Susan J Geyer, BA     801-536-3561     sgeyer@shrinenet.org    
Principal Investigator: Jacques D'Astous, MD            
Sponsors and Collaborators
Shriners Hospitals for Children
University of Utah
Investigators
Principal Investigator: John C Carey, MD, MPH University of Utah, Health Science Center
  More Information

Responsible Party: Shriners Hospitals for Children ( John C. Carey, MD )
Study ID Numbers: 9165
Study First Received: March 14, 2006
Last Updated: May 20, 2008
ClinicalTrials.gov Identifier: NCT00303368  
Health Authority: United States: Institutional Review Board

Keywords provided by Shriners Hospitals for Children:
Neurofibromatosis (NF1)
Tibial Dysplasia (TD)

Study placed in the following topic categories:
Heredodegenerative Disorders, Nervous System
Neoplastic Syndromes, Hereditary
Neuromuscular Diseases
Genetic Diseases, Inborn
Neurofibroma
Peripheral Nervous System Diseases
Neurofibromatoses
Neurodegenerative Diseases
Neurofibromatosis type 1
Nerve Sheath Neoplasms
Neurofibromatosis 1
Neurocutaneous Syndromes

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Nervous System Diseases
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on January 16, 2009